The purpose of this study is to understand more about the combination of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) who have a specific mutation in the EGFR (epidermal growth factor receptor) gene and have not had prior treatment for their disease. The Food and Drug Administration (FDA) has not approved the combination of amivantamab…
The purpose of this research study is to determine the effectiveness and safety of envafolimab, an experimental drug that is not approved for use, when given alone or in combination with ipilimumab to stimulate your immune system to attack cancer cells. Envafolimab is an experimental (investigational) cancer drug that overrides the PD-1/PD-L1 checkpoint,…